Compare JLS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JLS | CMMB |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.9M | 13.8M |
| IPO Year | N/A | N/A |
| Metric | JLS | CMMB |
|---|---|---|
| Price | $18.42 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 26.6K | ★ 92.9K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.48 | $1.60 |
| 52 Week High | $17.97 | $8.80 |
| Indicator | JLS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 36.59 |
| Support Level | $18.06 | $1.70 |
| Resistance Level | $18.25 | $1.93 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 97.50 | 33.51 |
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.